Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DLCL002 Protocol for High-Risk Aggressive B-cell Lymphoma
NCT03837873Phase 2Unknown
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2019
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, etoposide, dexamethasone, vincristine, cyclophosphamide in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), transformed lymphoma, sponsored by Institute of Hematology and Blood Diseases Hospital. Status: unknown.
02
Drugs
rituximabetoposidedexamethasonevincristinecyclophosphamide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)transformed lymphoma
Beyond the preview
Go deeper on NCT03837873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03837873.